B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.